Pentixapharm Holding AG PTP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €1.85
- Day Range
- €1.84–1.89
- 52-Week Range
- €1.30–3.70
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 500,000.00
- Market Cap
- €932,500.00
- Volume/Avg
- 4,108 / 22,866
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 610.47
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 38
- Website
- https://www.pentixapharm.com
Valuation
|
Metric
|
PTP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.69 |
Price/Sales | 610.47 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PTP
|
|---|---|
Quick Ratio | 1.26 |
Current Ratio | 1.55 |
Interest Coverage | — |
Quick Ratio
PTP
Profitability
|
Metric
|
PTP
|
|---|---|
Return on Assets (Normalized) | −34.47% |
Return on Equity (Normalized) | −42.85% |
Return on Invested Capital (Normalized) | −43.45% |
Return on Assets
PTP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|z@%^@h% | LOCK|P$FC# | $129B | |||
| Moderna Inc
MRNA
| LOCK|Q^NbG! | LOCK|Q$ | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|NPnp>Rx | LOCK|lSJ^ | $77B | |||
| argenx SE ADR
ARGX
| LOCK|p%<F$@ | LOCK|>@ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|cW?cW$ | LOCK|$qp | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$?$kmw | LOCK|yk@^ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|zy$l^SGj | LOCK|<%s% | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|XTWb$rY | LOCK|km? | $24B | |||
| Incyte Corp
INCY
| LOCK|qcN#J! | LOCK|P!# | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@T%j<C | LOCK|yJ | $14B |
United States